Importantly, patients with stage IA EGFR-positive NSCLC had a recurrence risk comparable to those with stage IB, and 37.2% of patients with stage IB-IIIA were cured without adjuvant osimertinib, which is a relevant concern in light of ADAURA. Here, EGFR is linked to non-small cell lung carcinoma.